Pandemic H5N1 vaccine - Tria Bioscience/Immune Design
Latest Information Update: 14 Jul 2016
At a glance
- Originator TRIA Bioscience
- Developer Immune Design; TRIA Bioscience
- Class Influenza A virus H5N1 vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Influenza A virus H5N1 subtype
Most Recent Events
- 14 Jul 2016 Preclinical trials in Influenza-A virus H5N1 subtype (Prevention) in USA (unspecified route)